TD-1473

DRUG3 trials

Sponsors

Theravance Biopharma

Conditions

Crohn's DiseaseInflammatory Bowel DiseaseUlcerative Colitis, Active ModerateUlcerative Colitis, Active Severe

Phase 1

TD-1473 for Active Ulcerative Colitis (UC)

CompletedNCT02818686

Theravance BiopharmaUlcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe

Start: 2016-10-03End: 2018-03-29Updated: 2021-09-30

Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study

CompletedNCT03555617

Theravance BiopharmaInflammatory Bowel Disease

Start: 2018-06-13End: 2018-07-15Updated: 2021-01-14

Phase 2

Efficacy and Safety of TD-1473 in Crohn's Disease

TerminatedNCT03635112

Theravance BiopharmaCrohn's Disease

Start: 2018-11-19End: 2021-12-30Updated: 2023-03-13

Related Papers

Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme

Journal of Crohn s and Colitis2020-03-0680 citations